行为经济学激励支持HIV治疗依从性(BEST):乌干达随机对照试验方案
该试验在乌干达Mildmay医院纳入330例HIV阳性患者,随机分为三组:以按时就诊和病毒抑制为条件的小额彩票奖励组、以MEMS帽测量的高依从性为条件的同等奖励组,以及常规标准照护对照组。主要结局为病毒载量是否可检测及MEMS测量的依从性,并评估干预后12个月的效果持续性。
要点
- 彩票奖励分别以病毒抑制和电子监测依从性为条件,比较两种实施方式的效果。
- 主要结局为病毒载量可检测性与MEMS测量的依从性。
- 干预结束后随访12个月,评估效果是否持续。
核心结论
- 在乌干达HIV阳性患者中检验根植于行为经济学的彩票激励能否克服现时偏向、提高ART依从性。
- 比较以病毒抑制为条件与以电子监测依从性为条件两种彩票资格判定方式的相对效果。
- 将对两种实施方式开展成本效果分析。
研究设计与样本
- 在乌干达坎帕拉Mildmay医院开展的2年随机对照试验,计划纳入330例HIV阳性患者。
- 参与者随机分为三组:T1组(n=110)以按时就诊和病毒抑制为彩票资格条件。
- T2组(n=110)以MEMS帽测量的高依从性为彩票资格条件;对照组(n=110)接受常规标准照护。
- 干预期间持续测量依从性,并在干预后12个月继续测量以评估效果持续性。
- 基线及此后每6个月开展问卷调查,每年测量病毒载量。
关键数值与推荐
- 主要结局为病毒载量是否可检测,以及MEMS测量的依从性。
- 次要结局包括对数转换的病毒载量连续指标,以及是否服用至少90%ART药片的二分类指标。
- 试验注册号ClinicalTrials.gov NCT03494777,2018年4月11日注册。
临床怎么用
- MEMS帽成本相对较高,而病毒载量检测在乌干达已属常规临床照护。
- 若直接激励病毒抑制与激励电子监测依从性效果相当,可利用现成临床数据实施激励。
- 成本效果分析结果可为两种实施方式的选择提供依据。
局限性
- 原文为试验方案,尚未报告干预效果数据。
- 研究在乌干达单一医院开展,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many HIV-positive patients do not appropriately adhere to their antiretroviral medication (ART). This leads to higher viral loads and greater probability of HIV transmission. Present bias-a tendency to give in to short-term temptations at the expense of long-term outcomes-is a potential driver of low adherence. In this study we test a novel intervention rooted in behavioral economics that is designed to overcome present bias and increase ART adherence. METHODS/DESIGN: We will enroll 330 HIV-positive patients at Mildmay Hospital in Kampala, Uganda, into a 2-year randomized controlled trial. Participants will be randomized to one of three groups. The first intervention group (T1, n = 110) will be eligible for small lottery prizes based on timely clinic visits and demonstration of viral suppression. Group 2 (T2, n = 110) will be eligible for the same lottery prizes conditional on high adherence measured by a medication event management system (MEMS) cap. The control group (n = 110) will receive the usual standard of care. Adherence will be measured continuously throughout the intervention period and for 12 months post-intervention to evaluate effect persistence. Surveys will be conducted at baseline and then every 6 months. Viral loads will be measured annually. Primary outcomes are whether the viral load is detectable and MEMS-measured adherence. Secondary outcomes are the log-transformed viral load as a continuous measure and a binary measure for whether the person took at least 90% of their ART pills. DISCUSSION: Our study is one of the first to investigate the effectiveness of lottery incentives for improving ART adherence, and in addition, it compares the relative efficacy of using electronically measured adherence versus viral load to determine lottery eligibility. MEMS caps are relatively costly, whereas viral load testing is now part of routine clinical care in Uganda. BEST will test whether directly incentivizing viral suppression (which can be implemented using readily available clinic data) is as effective as incentivizing electronically measured adherence. Cost-effectiveness analyses of the two implementation modes will also be performed. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03494777. Registered on 11 April 2018.
引用
- Linnemayr S, Stecher C, Saya U, et al. Behavioral Economics Incentives to Support HIV Treatment Adherence (BEST): Protocol for a randomized controlled trial in Uganda. Trials. 2020. PMID: 31900193. doi:10.1186/s13063-019-3795-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。